IL297309A - Modulation of T-cell cytotoxicity and related therapy - Google Patents

Info

Publication number

IL297309A

IL297309A IL297309A IL29730922A IL297309A IL 297309 A IL297309 A IL 297309A IL 297309 A IL297309 A IL 297309A IL 29730922 A IL29730922 A IL 29730922A IL 297309 A IL297309 A IL 297309A

Authority

IL

Israel

Prior art keywords

cell

engineered

sirpg

tumour

genes

Prior art date

2020-04-17

Links

• Espacenet
• Global Dossier
• Discuss

• 238000002560 therapeutic procedure Methods 0.000 title claims description 14
• 230000003013 cytotoxicity Effects 0.000 title description 9
• 231100000135 cytotoxicity Toxicity 0.000 title description 9
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 487
• 108090000623 proteins and genes Proteins 0.000 claims description 255
• 206010028980 Neoplasm Diseases 0.000 claims description 242
• 230000014509 gene expression Effects 0.000 claims description 167
• 210000004027 cell Anatomy 0.000 claims description 143
• 101000835928 Homo sapiens Signal-regulatory protein gamma Proteins 0.000 claims description 133
• 102100025795 Signal-regulatory protein gamma Human genes 0.000 claims description 130
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 117
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 117
• 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 claims description 113
• 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 claims description 111
• 101150111025 Furin gene Proteins 0.000 claims description 96
• 102000004961 Furin Human genes 0.000 claims description 95
• 101000820460 Homo sapiens Stomatin Proteins 0.000 claims description 93
• 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims description 92
• 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 92
• 238000000034 method Methods 0.000 claims description 92
• 101000846910 Homo sapiens Fc receptor-like protein 3 Proteins 0.000 claims description 90
• 102100021685 Stomatin Human genes 0.000 claims description 90
• 102100031512 Fc receptor-like protein 3 Human genes 0.000 claims description 87
• 230000000694 effects Effects 0.000 claims description 81
• 101001092917 Homo sapiens SAM domain-containing protein SAMSN-1 Proteins 0.000 claims description 76
• 102100036195 SAM domain-containing protein SAMSN-1 Human genes 0.000 claims description 74
• 101000914469 Homo sapiens CD82 antigen Proteins 0.000 claims description 72
• 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 72
• 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 71
• -1 C5ORF30 Proteins 0.000 claims description 70
• 102100027217 CD82 antigen Human genes 0.000 claims description 68
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 64
• 201000005249 lung adenocarcinoma Diseases 0.000 claims description 64
• 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 claims description 53
• 108091008874 T cell receptors Proteins 0.000 claims description 53
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 53
• 101000663002 Homo sapiens TNFAIP3-interacting protein 3 Proteins 0.000 claims description 52
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
• 101000696705 Homo sapiens Histone-lysine N-methyltransferase SUV39H1 Proteins 0.000 claims description 51
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 51
• 108010055211 EphA1 Receptor Proteins 0.000 claims description 50
• 102100030322 Ephrin type-A receptor 1 Human genes 0.000 claims description 50
• 102100037666 TNFAIP3-interacting protein 3 Human genes 0.000 claims description 50
• 102100028998 Histone-lysine N-methyltransferase SUV39H1 Human genes 0.000 claims description 49
• 238000011282 treatment Methods 0.000 claims description 49
• 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 claims description 47
• 201000011510 cancer Diseases 0.000 claims description 47
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 46
• 101001062855 Homo sapiens Fatty acid-binding protein 5 Proteins 0.000 claims description 46
• 101001050472 Homo sapiens Integral membrane protein 2A Proteins 0.000 claims description 46
• 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 claims description 46
• 102100026099 Claudin domain-containing protein 1 Human genes 0.000 claims description 45
• 101000912657 Homo sapiens Claudin domain-containing protein 1 Proteins 0.000 claims description 45
• 102100030421 Fatty acid-binding protein 5 Human genes 0.000 claims description 44
• 101000583692 Homo sapiens Pleckstrin homology-like domain family A member 1 Proteins 0.000 claims description 43
• 102100023351 Integral membrane protein 2A Human genes 0.000 claims description 43
• 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 claims description 42
• 101001103771 Homo sapiens Ribonuclease H2 subunit A Proteins 0.000 claims description 42
• 102100039493 Ribonuclease H2 subunit A Human genes 0.000 claims description 42
• 102100029004 Zinc finger protein Gfi-1 Human genes 0.000 claims description 42
• 101000940352 Homo sapiens Coactosin-like protein Proteins 0.000 claims description 41
• 101001059220 Homo sapiens Zinc finger protein Gfi-1 Proteins 0.000 claims description 41
• 101710140408 Regulator of G-protein signaling 1 Proteins 0.000 claims description 41
• 239000003112 inhibitor Substances 0.000 claims description 41
• 102100031552 Coactosin-like protein Human genes 0.000 claims description 40
• 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 claims description 40
• 102100030887 Pleckstrin homology-like domain family A member 1 Human genes 0.000 claims description 40
• 102100021269 Regulator of G-protein signaling 1 Human genes 0.000 claims description 40
• 101710140412 Regulator of G-protein signaling 2 Proteins 0.000 claims description 40
• 102100021258 Regulator of G-protein signaling 2 Human genes 0.000 claims description 39
• 101150029755 park gene Proteins 0.000 claims description 38
• 208000035475 disorder Diseases 0.000 claims description 36
• 238000009169 immunotherapy Methods 0.000 claims description 35
• 102000004169 proteins and genes Human genes 0.000 claims description 34
• 230000002062 proliferating effect Effects 0.000 claims description 29
• 102100039767 Ras-related protein Rab-27A Human genes 0.000 claims description 28
• 108010033990 rab27 GTP-Binding Proteins Proteins 0.000 claims description 28
• 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 26
• 239000012636 effector Substances 0.000 claims description 25
• 239000004055 small Interfering RNA Substances 0.000 claims description 24
• 230000001965 increasing effect Effects 0.000 claims description 22
• 210000004698 lymphocyte Anatomy 0.000 claims description 22
• 230000002829 reductive effect Effects 0.000 claims description 20
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 19
• 239000012190 activator Substances 0.000 claims description 18
• 108091033409 CRISPR Proteins 0.000 claims description 15
• 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 claims description 14
• 208000020816 lung neoplasm Diseases 0.000 claims description 14
• 150000003384 small molecules Chemical group 0.000 claims description 14
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 13
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 13
• 201000005202 lung cancer Diseases 0.000 claims description 13
• 102000039446 nucleic acids Human genes 0.000 claims description 13
• 150000007523 nucleic acids Chemical class 0.000 claims description 13
• 108700011259 MicroRNAs Proteins 0.000 claims description 12
• 102100034485 Ras-related protein Rab-2A Human genes 0.000 claims description 12
• 108091027967 Small hairpin RNA Proteins 0.000 claims description 12
• 108020004459 Small interfering RNA Proteins 0.000 claims description 12
• 238000010459 TALEN Methods 0.000 claims description 12
• 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 12
• 230000001404 mediated effect Effects 0.000 claims description 12
• 201000001441 melanoma Diseases 0.000 claims description 12
• 239000002679 microRNA Substances 0.000 claims description 12
• 108020004707 nucleic acids Proteins 0.000 claims description 12
• 108010067765 rab2 GTP Binding protein Proteins 0.000 claims description 12
• 230000003828 downregulation Effects 0.000 claims description 11
• 230000008595 infiltration Effects 0.000 claims description 11
• 238000001764 infiltration Methods 0.000 claims description 11
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
• 238000002659 cell therapy Methods 0.000 claims description 10
• 230000002708 enhancing effect Effects 0.000 claims description 10
• 238000000338 in vitro Methods 0.000 claims description 10
• 230000001472 cytotoxic effect Effects 0.000 claims description 9
• 239000013598 vector Substances 0.000 claims description 9
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 8
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 8
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 8
• 239000012634 fragment Substances 0.000 claims description 8
• 230000005746 immune checkpoint blockade Effects 0.000 claims description 8
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 8
• 206010027406 Mesothelioma Diseases 0.000 claims description 7
• 238000004519 manufacturing process Methods 0.000 claims description 7
• 230000002018 overexpression Effects 0.000 claims description 7
• 230000009261 transgenic effect Effects 0.000 claims description 7
• 238000010354 CRISPR gene editing Methods 0.000 claims description 6
• 206010009944 Colon cancer Diseases 0.000 claims description 6
• 102100037499 Parkinson disease protein 7 Human genes 0.000 claims description 6
• 230000017188 evasion or tolerance of host immune response Effects 0.000 claims description 6
• 238000010362 genome editing Methods 0.000 claims description 6
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
• 230000028993 immune response Effects 0.000 claims description 6
• 230000001052 transient effect Effects 0.000 claims description 6
• 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 5
• 206010005003 Bladder cancer Diseases 0.000 claims description 5
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 5
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
• 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 5
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
• 206010014733 Endometrial cancer Diseases 0.000 claims description 5
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
• 108010032428 Protein Deglycase DJ-1 Proteins 0.000 claims description 5
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
• 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 5
• 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 5
• 201000010881 cervical cancer Diseases 0.000 claims description 5
• 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 5
• 206010017758 gastric cancer Diseases 0.000 claims description 5
• 201000010536 head and neck cancer Diseases 0.000 claims description 5
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
• 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 5
• 201000010198 papillary carcinoma Diseases 0.000 claims description 5
• 201000011549 stomach cancer Diseases 0.000 claims description 5
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
• 239000000556 agonist Substances 0.000 claims description 4
• 229940022399 cancer vaccine Drugs 0.000 claims description 4
• 238000012258 culturing Methods 0.000 claims description 4
• 239000003446 ligand Substances 0.000 claims description 4
• 206010006187 Breast cancer Diseases 0.000 claims description 3
• 208000026310 Breast neoplasm Diseases 0.000 claims description 3
• 206010025323 Lymphomas Diseases 0.000 claims description 3
• 206010033128 Ovarian cancer Diseases 0.000 claims description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
• 206010060862 Prostate cancer Diseases 0.000 claims description 3
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
• 230000000903 blocking effect Effects 0.000 claims description 3
• 208000032839 leukemia Diseases 0.000 claims description 3
• 201000007270 liver cancer Diseases 0.000 claims description 3
• 208000014018 liver neoplasm Diseases 0.000 claims description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
• 201000002528 pancreatic cancer Diseases 0.000 claims description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
• 206010038389 Renal cancer Diseases 0.000 claims description 2
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
• 201000002313 intestinal cancer Diseases 0.000 claims description 2
• 201000010982 kidney cancer Diseases 0.000 claims description 2
• 201000002510 thyroid cancer Diseases 0.000 claims description 2
• 201000009657 thyroid sarcoma Diseases 0.000 claims description 2
• 102100024026 Transcription factor E2F1 Human genes 0.000 claims 12
• 230000002222 downregulating effect Effects 0.000 claims 2
• 238000000684 flow cytometry Methods 0.000 description 74
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 55
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 55
• 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 52
• 238000003559 RNA-seq method Methods 0.000 description 45
• 238000004458 analytical method Methods 0.000 description 43
• 230000024245 cell differentiation Effects 0.000 description 40
• 125000003275 alpha amino acid group Chemical group 0.000 description 34
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 32
• 239000000427 antigen Substances 0.000 description 31
• 108091007433 antigens Proteins 0.000 description 31
• 102000036639 antigens Human genes 0.000 description 31
• 230000000869 mutational effect Effects 0.000 description 30
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 24
• 210000004881 tumor cell Anatomy 0.000 description 24
• 238000012174 single-cell RNA sequencing Methods 0.000 description 22
• 210000001519 tissue Anatomy 0.000 description 21
• 238000003501 co-culture Methods 0.000 description 20
• 230000004069 differentiation Effects 0.000 description 20
• 230000004083 survival effect Effects 0.000 description 20
• 239000003814 drug Substances 0.000 description 19
• 239000000523 sample Substances 0.000 description 19
• 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 18
• 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 18
• 239000003550 marker Substances 0.000 description 18
• 230000002596 correlated effect Effects 0.000 description 17
• 230000035772 mutation Effects 0.000 description 17
• 201000010099 disease Diseases 0.000 description 16
• 230000011664 signaling Effects 0.000 description 16
• 230000004064 dysfunction Effects 0.000 description 15
• 230000004547 gene signature Effects 0.000 description 15
• 239000000203 mixture Substances 0.000 description 15
• 230000000638 stimulation Effects 0.000 description 15
• 230000002103 transcriptional effect Effects 0.000 description 15
• 238000010199 gene set enrichment analysis Methods 0.000 description 14
• 230000006870 function Effects 0.000 description 13
• 206010069754 Acquired gene mutation Diseases 0.000 description 12
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 12
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 12
• 230000005764 inhibitory process Effects 0.000 description 12
• 230000037439 somatic mutation Effects 0.000 description 12
• 238000012360 testing method Methods 0.000 description 12
• 238000010200 validation analysis Methods 0.000 description 12
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 11
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 11
• 238000012546 transfer Methods 0.000 description 11
• 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 10
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 10
• 230000008859 change Effects 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 230000000259 anti-tumor effect Effects 0.000 description 9
• 230000030741 antigen processing and presentation Effects 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 8
• 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 8
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 8
• 238000002512 chemotherapy Methods 0.000 description 8
• 101000653540 Homo sapiens Transcription factor 7 Proteins 0.000 description 7
• 230000006044 T cell activation Effects 0.000 description 7
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 7
• 239000008194 pharmaceutical composition Substances 0.000 description 7
• 102000005962 receptors Human genes 0.000 description 7
• 108020003175 receptors Proteins 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 7
• 108010012236 Chemokines Proteins 0.000 description 6
• 102000019034 Chemokines Human genes 0.000 description 6
• 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 6
• 101000578928 Homo sapiens Macrophage immunometabolism regulator Proteins 0.000 description 6
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 210000003719 b-lymphocyte Anatomy 0.000 description 6
• 238000012512 characterization method Methods 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 230000001684 chronic effect Effects 0.000 description 6
• 238000004163 cytometry Methods 0.000 description 6
• 230000007547 defect Effects 0.000 description 6
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 102000004196 processed proteins & peptides Human genes 0.000 description 6
• 230000000069 prophylactic effect Effects 0.000 description 6
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 6
• 238000007482 whole exome sequencing Methods 0.000 description 6
• 108010024976 Asparaginase Proteins 0.000 description 5
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 5
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 5
• 102100027581 Forkhead box protein P3 Human genes 0.000 description 5
• 101000749331 Homo sapiens Claudin-1 Proteins 0.000 description 5
• 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 5
• 101000972291 Homo sapiens Lymphoid enhancer-binding factor 1 Proteins 0.000 description 5
• 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 5
• 102100022699 Lymphoid enhancer-binding factor 1 Human genes 0.000 description 5
• 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 5
• 238000000585 Mann–Whitney U test Methods 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
• 102100030627 Transcription factor 7 Human genes 0.000 description 5
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 5
• 238000009826 distribution Methods 0.000 description 5
• 238000010195 expression analysis Methods 0.000 description 5
• GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 5
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 5
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 210000003289 regulatory T cell Anatomy 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 238000010186 staining Methods 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 5
• KXMZDGSRSGHMMK-VWLOTQADSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[(7s)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1([C@H]2CCC3=CC=C(C=C3CC2)NC=2N=C(N(N=2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)N)CCCC1 KXMZDGSRSGHMMK-VWLOTQADSA-N 0.000 description 4
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 4
• 102100027207 CD27 antigen Human genes 0.000 description 4
• 201000009030 Carcinoma Diseases 0.000 description 4
• 102000009410 Chemokine receptor Human genes 0.000 description 4
• 108050000299 Chemokine receptor Proteins 0.000 description 4
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
• 108010092160 Dactinomycin Proteins 0.000 description 4
• 102100030751 Eomesodermin homolog Human genes 0.000 description 4
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 4
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 4
• 108010078049 Interferon alpha-2 Proteins 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• 102000000588 Interleukin-2 Human genes 0.000 description 4
• 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 4
• 238000003646 Spearman's rank correlation coefficient Methods 0.000 description 4
• 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 4
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 4
• 102000040945 Transcription factor Human genes 0.000 description 4
• 108091023040 Transcription factor Proteins 0.000 description 4
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 4
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
• 210000000612 antigen-presenting cell Anatomy 0.000 description 4
• 229950009568 bemcentinib Drugs 0.000 description 4
• 230000011712 cell development Effects 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 229960005420 etoposide Drugs 0.000 description 4
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 4
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
• 230000036039 immunity Effects 0.000 description 4
• 230000001771 impaired effect Effects 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 210000001165 lymph node Anatomy 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 229960004961 mechlorethamine Drugs 0.000 description 4
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 4
• 239000002773 nucleotide Substances 0.000 description 4
• 125000003729 nucleotide group Chemical group 0.000 description 4
• 238000001959 radiotherapy Methods 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 238000002255 vaccination Methods 0.000 description 4
• JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 4
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
• DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 3
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 3
• VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 3
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
• 102000015790 Asparaginase Human genes 0.000 description 3
• 108010006654 Bleomycin Proteins 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
• 229940045513 CTLA4 antagonist Drugs 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• 102100030385 Granzyme B Human genes 0.000 description 3
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
• 101100172508 Homo sapiens EPHA1 gene Proteins 0.000 description 3
• 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 description 3
• 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 3
• 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 3
• 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 3
• 108060003951 Immunoglobulin Proteins 0.000 description 3
• SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 3
• 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
• 102100028329 Macrophage immunometabolism regulator Human genes 0.000 description 3
• 101100445364 Mus musculus Eomes gene Proteins 0.000 description 3
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
• 108010016076 Octreotide Proteins 0.000 description 3
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 3
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 3
• 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 3
• 101100445365 Xenopus laevis eomes gene Proteins 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
• 238000000540 analysis of variance Methods 0.000 description 3
• 238000011130 autologous cell therapy Methods 0.000 description 3
• 229940120638 avastin Drugs 0.000 description 3
• DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 3
• 229960000397 bevacizumab Drugs 0.000 description 3
• 208000035269 cancer or benign tumor Diseases 0.000 description 3
• 210000004970 cd4 cell Anatomy 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 229960005395 cetuximab Drugs 0.000 description 3
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
• 230000000139 costimulatory effect Effects 0.000 description 3
• 108091008034 costimulatory receptors Proteins 0.000 description 3
• 229960000640 dactinomycin Drugs 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 230000009274 differential gene expression Effects 0.000 description 3
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
• 229960004679 doxorubicin Drugs 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
• LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 3
• 229960000752 etoposide phosphate Drugs 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
• 235000008191 folinic acid Nutrition 0.000 description 3
• 239000011672 folinic acid Substances 0.000 description 3
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 102000018358 immunoglobulin Human genes 0.000 description 3
• 108091008042 inhibitory receptors Proteins 0.000 description 3
• 229960005280 isotretinoin Drugs 0.000 description 3
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 3
• 238000012417 linear regression Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 3
• 229960001428 mercaptopurine Drugs 0.000 description 3
• 229960004857 mitomycin Drugs 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 238000010202 multivariate logistic regression analysis Methods 0.000 description 3
• 206010061311 nervous system neoplasm Diseases 0.000 description 3
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 230000009257 reactivity Effects 0.000 description 3
• 238000000611 regression analysis Methods 0.000 description 3
• 230000000717 retained effect Effects 0.000 description 3
• 229960004641 rituximab Drugs 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 238000012163 sequencing technique Methods 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
• 229960001278 teniposide Drugs 0.000 description 3
• 229960003087 tioguanine Drugs 0.000 description 3
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
• 229960004528 vincristine Drugs 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
• 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
• CYNZBLNMIJNBSF-UHFFFAOYSA-N 7-[(4-ethoxy-3-methylphenyl)-(pyridin-2-ylamino)methyl]-2-methylquinolin-8-ol Chemical compound C1=C(C)C(OCC)=CC=C1C(C=1C(=C2N=C(C)C=CC2=CC=1)O)NC1=CC=CC=N1 CYNZBLNMIJNBSF-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 101150106774 9 gene Proteins 0.000 description 2
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
• 206010003445 Ascites Diseases 0.000 description 2
• 206010003571 Astrocytoma Diseases 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
• 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 2
• 108700031361 Brachyury Proteins 0.000 description 2
• 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
• 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
• 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 2
• 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
• 102100040836 Claudin-1 Human genes 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 108010019673 Darbepoetin alfa Proteins 0.000 description 2
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
• 108010074604 Epoetin Alfa Proteins 0.000 description 2
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
• 108010029961 Filgrastim Proteins 0.000 description 2
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
• 206010018338 Glioma Diseases 0.000 description 2
• 108010069236 Goserelin Proteins 0.000 description 2
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 102000001398 Granzyme Human genes 0.000 description 2
• 108060005986 Granzyme Proteins 0.000 description 2
• 108010058597 HLA-DR Antigens Proteins 0.000 description 2
• 102000006354 HLA-DR Antigens Human genes 0.000 description 2
• 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 2
• 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 2
• 101001022148 Homo sapiens Furin Proteins 0.000 description 2
• 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
• 101000601727 Homo sapiens Parkinson disease protein 7 Proteins 0.000 description 2
• 101000744527 Homo sapiens Ras-related protein Rab-27A Proteins 0.000 description 2
• 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 2
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 102100022341 Integrin alpha-E Human genes 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
• 108010000817 Leuprolide Proteins 0.000 description 2
• 108010052014 Liberase Proteins 0.000 description 2
• 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• 108091007960 PI3Ks Proteins 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 2
• 102000004503 Perforin Human genes 0.000 description 2
• 108010056995 Perforin Proteins 0.000 description 2
• KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
• 208000037581 Persistent Infection Diseases 0.000 description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 238000011529 RT qPCR Methods 0.000 description 2
• 101710099920 Recombining binding protein suppressor of hairless Proteins 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
• 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
• 102000008889 TNF receptor-associated factor TRAF Human genes 0.000 description 2
• 108050000808 TNF receptor-associated factor TRAF Proteins 0.000 description 2
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 108700025316 aldesleukin Proteins 0.000 description 2
• 229960000548 alemtuzumab Drugs 0.000 description 2
• 229960000473 altretamine Drugs 0.000 description 2
• JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
• 229960003437 aminoglutethimide Drugs 0.000 description 2
• OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 2
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 2
• 229960003272 asparaginase Drugs 0.000 description 2
• 229960003852 atezolizumab Drugs 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 229950002916 avelumab Drugs 0.000 description 2
• 108010023337 axl receptor tyrosine kinase Proteins 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 239000000090 biomarker Substances 0.000 description 2
• 229960001561 bleomycin Drugs 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 238000002619 cancer immunotherapy Methods 0.000 description 2
• 229960004562 carboplatin Drugs 0.000 description 2
• 229960005243 carmustine Drugs 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 230000011748 cell maturation Effects 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 229940044683 chemotherapy drug Drugs 0.000 description 2
• 229960004630 chlorambucil Drugs 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• 238000010219 correlation analysis Methods 0.000 description 2
• 230000000875 corresponding effect Effects 0.000 description 2
• BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 2
• 238000011262 co‐therapy Methods 0.000 description 2
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 238000007405 data analysis Methods 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 229960000605 dexrazoxane Drugs 0.000 description 2
• 229960003668 docetaxel Drugs 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• YUAALFPUEOYPNX-UHFFFAOYSA-N dubermatinib Chemical compound CN(C)S(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C=CC(CN3CCN(C)CC3)=CC=2)=NC=C1Cl YUAALFPUEOYPNX-UHFFFAOYSA-N 0.000 description 2
• 229940121552 dubermatinib Drugs 0.000 description 2
• 229950009791 durvalumab Drugs 0.000 description 2
• 230000008482 dysregulation Effects 0.000 description 2
• 229960001904 epirubicin Drugs 0.000 description 2
• 229960001433 erlotinib Drugs 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 230000009760 functional impairment Effects 0.000 description 2
• 229960002584 gefitinib Drugs 0.000 description 2
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
• IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
• 238000001794 hormone therapy Methods 0.000 description 2
• 102000045407 human CD82 Human genes 0.000 description 2
• 102000049940 human CLDN1 Human genes 0.000 description 2
• 102000051559 human COTL1 Human genes 0.000 description 2
• 102000051429 human DUSP4 Human genes 0.000 description 2
• 102000050313 human E2F1 Human genes 0.000 description 2
• 102000047031 human FABP5 Human genes 0.000 description 2
• 102000056877 human FCRL3 Human genes 0.000 description 2
• 102000050253 human FURIN Human genes 0.000 description 2
• 102000046828 human IL1RAP Human genes 0.000 description 2
• 102000053813 human ITM2A Human genes 0.000 description 2
• 102000054831 human PARK7 Human genes 0.000 description 2
• 102000046661 human PECAM1 Human genes 0.000 description 2
• 102000047661 human PHLDA1 Human genes 0.000 description 2
• 102000045923 human RAB27A Human genes 0.000 description 2
• 102000048877 human RBPJ Human genes 0.000 description 2
• 102000054510 human SIRPG Human genes 0.000 description 2
• 102000058183 human STOM Human genes 0.000 description 2
• 102000054786 human SUV39H1 Human genes 0.000 description 2
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
• 229960001101 ifosfamide Drugs 0.000 description 2
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 230000004068 intracellular signaling Effects 0.000 description 2
• 238000010212 intracellular staining Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
• 229960005386 ipilimumab Drugs 0.000 description 2
• 229960004768 irinotecan Drugs 0.000 description 2
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
• 229960001691 leucovorin Drugs 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 208000037841 lung tumor Diseases 0.000 description 2
• 229960001924 melphalan Drugs 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 229960004584 methylprednisolone Drugs 0.000 description 2
• 230000002297 mitogenic effect Effects 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 210000000214 mouth Anatomy 0.000 description 2
• 201000005962 mycosis fungoides Diseases 0.000 description 2
• IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 2
• 229960002653 nilutamide Drugs 0.000 description 2
• 229960003301 nivolumab Drugs 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
• 229960001972 panitumumab Drugs 0.000 description 2
• 229960002621 pembrolizumab Drugs 0.000 description 2
• WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 2
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
• 229930192851 perforin Natural products 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 238000003908 quality control method Methods 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
• 230000008844 regulatory mechanism Effects 0.000 description 2
• 238000002271 resection Methods 0.000 description 2
• 230000000284 resting effect Effects 0.000 description 2
• 108090000731 ribonuclease HII Proteins 0.000 description 2
• 230000037432 silent mutation Effects 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• 239000000021 stimulant Substances 0.000 description 2
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 2
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
• 230000008093 supporting effect Effects 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 229960000235 temsirolimus Drugs 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 229960000303 topotecan Drugs 0.000 description 2
• 229960005267 tositumomab Drugs 0.000 description 2
• 238000012549 training Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 229960000575 trastuzumab Drugs 0.000 description 2
• 229950007217 tremelimumab Drugs 0.000 description 2
• 238000007492 two-way ANOVA Methods 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 2
• GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
• 229960002066 vinorelbine Drugs 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
• XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
• NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
• VNTHYLVDGVBPOU-QQYBVWGSSA-N (7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 VNTHYLVDGVBPOU-QQYBVWGSSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• VHRSUDSXCMQTMA-UHFFFAOYSA-N 11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC12C=CC(=O)C=C1C(C)CC1C2C(O)CC2(C)C(O)(C(=O)CO)CCC21 VHRSUDSXCMQTMA-UHFFFAOYSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical compound NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 description 1
• QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
• 101150051922 29 gene Proteins 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 description 1
• ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
• QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
• SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 101100452478 Arabidopsis thaliana DHAD gene Proteins 0.000 description 1
• 101000980998 Arabidopsis thaliana Phosphatidate cytidylyltransferase 4, chloroplastic Proteins 0.000 description 1
• 101150018445 Axl gene Proteins 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 108010074708 B7-H1 Antigen Proteins 0.000 description 1
• 241000283725 Bos Species 0.000 description 1
• 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
• 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
• 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
• 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
• 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
• 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
• 108010041397 CD4 Antigens Proteins 0.000 description 1
• 101150075764 CD4 gene Proteins 0.000 description 1
• 102100032937 CD40 ligand Human genes 0.000 description 1
• 101710139831 CD82 antigen Proteins 0.000 description 1
• 108091079001 CRISPR RNA Proteins 0.000 description 1
• 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
• 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 101710092479 Centrosomal protein of 55 kDa Proteins 0.000 description 1
• 102100031219 Centrosomal protein of 55 kDa Human genes 0.000 description 1
• 101150117721 Cht2 gene Proteins 0.000 description 1
• 102000004162 Claudin-1 Human genes 0.000 description 1
• 108090000600 Claudin-1 Proteins 0.000 description 1
• 101710105549 Coactosin-like protein Proteins 0.000 description 1
• 244000205754 Colocasia esculenta Species 0.000 description 1
• 235000006481 Colocasia esculenta Nutrition 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• 102100021906 Cyclin-O Human genes 0.000 description 1
• 239000012625 DNA intercalator Substances 0.000 description 1
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
• 101710132801 Dual specificity protein phosphatase 4 Proteins 0.000 description 1
• 102000015699 E2F1 Transcription Factor Human genes 0.000 description 1
• 108010063774 E2F1 Transcription Factor Proteins 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 101710201246 Eomesodermin Proteins 0.000 description 1
• 102100023688 Eotaxin Human genes 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 101710116744 Ephrin type-A receptor 1 Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 241000588698 Erwinia Species 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• 102000015212 Fas Ligand Protein Human genes 0.000 description 1
• 108010039471 Fas Ligand Protein Proteins 0.000 description 1
• 101710083187 Fatty acid-binding protein 5 Proteins 0.000 description 1
• 101710120222 Fc receptor-like protein 3 Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
• 241000295146 Gallionellaceae Species 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100021186 Granulysin Human genes 0.000 description 1
• 101710168479 Granulysin Proteins 0.000 description 1
• 101710119194 Histone-lysine N-methyltransferase SUV39H1 Proteins 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 1
• 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
• 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
• 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
• 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
• 101100113671 Homo sapiens CLDN1 gene Proteins 0.000 description 1
• 101100275405 Homo sapiens COTL1 gene Proteins 0.000 description 1
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
• 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
• 101100444097 Homo sapiens DUSP4 gene Proteins 0.000 description 1
• 101100064560 Homo sapiens E2F1 gene Proteins 0.000 description 1
• 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
• 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
• 101100446037 Homo sapiens FABP5 gene Proteins 0.000 description 1
• 101100503584 Homo sapiens FURIN gene Proteins 0.000 description 1
• 101100125859 Homo sapiens IL1RAP gene Proteins 0.000 description 1
• 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
• 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 description 1
• 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
• 101000957259 Homo sapiens Mitotic spindle assembly checkpoint protein MAD2A Proteins 0.000 description 1
• 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
• 101000978705 Homo sapiens Nephrocystin-4 Proteins 0.000 description 1
• 101000598495 Homo sapiens Nucleoporin Nup37 Proteins 0.000 description 1
• 101100243349 Homo sapiens PECAM1 gene Proteins 0.000 description 1
• 101100467597 Homo sapiens RAB27A gene Proteins 0.000 description 1
• 101100097133 Homo sapiens RBPJ gene Proteins 0.000 description 1
• 101100140882 Homo sapiens RGS1 gene Proteins 0.000 description 1
• 101100140897 Homo sapiens RGS2 gene Proteins 0.000 description 1
• 101100037765 Homo sapiens RNASEH2A gene Proteins 0.000 description 1
• 101001106523 Homo sapiens Regulator of G-protein signaling 1 Proteins 0.000 description 1
• 101001106672 Homo sapiens Regulator of G-protein signaling 2 Proteins 0.000 description 1
• 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 description 1
• 101100256990 Homo sapiens SIT1 gene Proteins 0.000 description 1
• 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
• 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 1
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
• 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 101710180843 Integral membrane protein 2A Proteins 0.000 description 1
• 102100025323 Integrin alpha-1 Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 description 1
• 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
• 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
• 102000057159 Kangai-1 Human genes 0.000 description 1
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 102100026894 Lymphotoxin-beta Human genes 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 102100038792 Mitotic spindle assembly checkpoint protein MAD2A Human genes 0.000 description 1
• 101100178241 Mus musculus Hnf1a gene Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
• 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
• 102100023192 Nephrocystin-4 Human genes 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 102100037837 Nucleoporin Nup37 Human genes 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 101100113376 Oryza sativa subsp. japonica Cht8 gene Proteins 0.000 description 1
• 235000021314 Palmitic acid Nutrition 0.000 description 1
• 101710097645 Parkinson disease protein 7 homolog Proteins 0.000 description 1
• 238000010220 Pearson correlation analysis Methods 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 108010079855 Peptide Aptamers Proteins 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 101710178746 Phosphatidate cytidylyltransferase 2 Proteins 0.000 description 1
• 102100033126 Phosphatidate cytidylyltransferase 2 Human genes 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 101710204736 Platelet endothelial cell adhesion molecule Proteins 0.000 description 1
• 101710134452 Pleckstrin homology-like domain family A member 1 Proteins 0.000 description 1
• 208000002151 Pleural effusion Diseases 0.000 description 1
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
• 101710142458 Protein/nucleic acid deglycase DJ-1 Proteins 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 101710137342 Ras-related protein Rab-27A Proteins 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102100024384 Replication termination factor 2 Human genes 0.000 description 1
• 101710175584 Replication termination factor 2 Proteins 0.000 description 1
• 101710133914 Ribonuclease H2 subunit A Proteins 0.000 description 1
• 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 description 1
• 101710089904 SAM domain-containing protein SAMSN-1 Proteins 0.000 description 1
• 102000038012 SFKs Human genes 0.000 description 1
• 108091008118 SFKs Proteins 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 101710092332 Signal-regulatory protein gamma Proteins 0.000 description 1
• 102100024453 Signaling threshold-regulating transmembrane adapter 1 Human genes 0.000 description 1
• 101710163815 Signaling threshold-regulating transmembrane adapter 1 Proteins 0.000 description 1
• 108700037714 Stomatin Proteins 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
• 101710193588 T-cell antigen CD7 Proteins 0.000 description 1
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
• 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
• 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 description 1
• 101710149775 TNFAIP3-interacting protein 3 Proteins 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 201000009365 Thymic carcinoma Diseases 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
• 101710192735 Tyrosine-protein kinase receptor UFO Proteins 0.000 description 1
• 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
• 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
• 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 101710145660 Zinc finger protein Gfi-1 Proteins 0.000 description 1
• FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
• 229960000446 abciximab Drugs 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 229940028652 abraxane Drugs 0.000 description 1
• XQEJFZYLWPSJOV-XJQYZYIXSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosa Chemical compound CC(O)=O.C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 XQEJFZYLWPSJOV-XJQYZYIXSA-N 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 102000035181 adaptor proteins Human genes 0.000 description 1
• 108091005764 adaptor proteins Proteins 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 210000001943 adrenal medulla Anatomy 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 229940064305 adrucil Drugs 0.000 description 1
• 229940042992 afinitor Drugs 0.000 description 1
• 229940060238 agrylin Drugs 0.000 description 1
• 229940060236 ala-cort Drugs 0.000 description 1
• 229960005310 aldesleukin Drugs 0.000 description 1
• 229940110282 alimta Drugs 0.000 description 1
• 229960001445 alitretinoin Drugs 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 229940098174 alkeran Drugs 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 229960001097 amifostine Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 229960001694 anagrelide Drugs 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 230000005975 antitumor immune response Effects 0.000 description 1
• 210000000436 anus Anatomy 0.000 description 1
• 238000002617 apheresis Methods 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 229940115115 aranesp Drugs 0.000 description 1
• 229940078010 arimidex Drugs 0.000 description 1
• 229940087620 aromasin Drugs 0.000 description 1
• 229940014583 arranon Drugs 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 229960004669 basiliximab Drugs 0.000 description 1
• 229960002707 bendamustine Drugs 0.000 description 1
• YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• 229960002938 bexarotene Drugs 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 229940108502 bicnu Drugs 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000003124 biologic agent Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 229960001467 bortezomib Drugs 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
• JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 229940112133 busulfex Drugs 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 229940112129 campath Drugs 0.000 description 1
• 229940088954 camptosar Drugs 0.000 description 1
• 238000009566 cancer vaccine Methods 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 229940097647 casodex Drugs 0.000 description 1
• 210000004534 cecum Anatomy 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 150000001875 compounds Chemical class 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 229940088547 cosmegen Drugs 0.000 description 1
• 230000004940 costimulation Effects 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229960002806 daclizumab Drugs 0.000 description 1
• 229940059359 dacogen Drugs 0.000 description 1
• 235000013365 dairy product Nutrition 0.000 description 1
• 229960005029 darbepoetin alfa Drugs 0.000 description 1
• 229960002448 dasatinib Drugs 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
• 229940041983 daunorubicin liposomal Drugs 0.000 description 1
• 229940107841 daunoxome Drugs 0.000 description 1
• 229940026692 decadron Drugs 0.000 description 1
• 229960003603 decitabine Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 229940027008 deltasone Drugs 0.000 description 1
• 108010017271 denileukin diftitox Proteins 0.000 description 1
• 238000000432 density-gradient centrifugation Methods 0.000 description 1
• 230000002074 deregulated effect Effects 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 229960003657 dexamethasone acetate Drugs 0.000 description 1
• 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
• PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
• 229940087410 dexasone Drugs 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 229940115080 doxil Drugs 0.000 description 1
• 230000002183 duodenal effect Effects 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• 229940073038 elspar Drugs 0.000 description 1
• 229940000733 emcyt Drugs 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
• 230000008995 epigenetic change Effects 0.000 description 1
• YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 229960003388 epoetin alfa Drugs 0.000 description 1
• 229940082789 erbitux Drugs 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 229940098617 ethyol Drugs 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 229960005167 everolimus Drugs 0.000 description 1
• 229940085363 evista Drugs 0.000 description 1
• 238000011124 ex vivo culture Methods 0.000 description 1
• 229960000255 exemestane Drugs 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 229940087861 faslodex Drugs 0.000 description 1
• 229940087476 femara Drugs 0.000 description 1
• 210000004700 fetal blood Anatomy 0.000 description 1
• 239000012997 ficoll-paque Substances 0.000 description 1
• 229960004177 filgrastim Drugs 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• 229960005304 fludarabine phosphate Drugs 0.000 description 1
• 229940064300 fluoroplex Drugs 0.000 description 1
• YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
• 229960001751 fluoxymesterone Drugs 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 229960002258 fulvestrant Drugs 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960000578 gemtuzumab Drugs 0.000 description 1
• 238000003197 gene knockdown Methods 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 229940084910 gliadel Drugs 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 229960002913 goserelin Drugs 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 229940003183 hexalen Drugs 0.000 description 1
• 102000044946 human BCL6 Human genes 0.000 description 1
• 102000049728 human MACIR Human genes 0.000 description 1
• 102000052095 human RGS1 Human genes 0.000 description 1
• 102000044011 human RGS2 Human genes 0.000 description 1
• 102000050211 human SAMSN1 Human genes 0.000 description 1
• 102000056290 human TNIP3 Human genes 0.000 description 1
• 229940088013 hycamtin Drugs 0.000 description 1
• 229940096120 hydrea Drugs 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 229950000785 hydrocortisone phosphate Drugs 0.000 description 1
• 229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 1
• 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
• VWQWXZAWFPZJDA-CGVGKPPMSA-N hydrocortisone succinate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 VWQWXZAWFPZJDA-CGVGKPPMSA-N 0.000 description 1
• 229940099279 idamycin Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 229940090411 ifex Drugs 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 102000027596 immune receptors Human genes 0.000 description 1
• 108091008915 immune receptors Proteins 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 238000003365 immunocytochemistry Methods 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229960003521 interferon alfa-2a Drugs 0.000 description 1
• 229960003507 interferon alfa-2b Drugs 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 229940065638 intron a Drugs 0.000 description 1
• 229940084651 iressa Drugs 0.000 description 1
• 229960002014 ixabepilone Drugs 0.000 description 1
• FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
• 210000001630 jejunum Anatomy 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 229960004891 lapatinib Drugs 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 229960004942 lenalidomide Drugs 0.000 description 1
• 229960003881 letrozole Drugs 0.000 description 1
• 229940063725 leukeran Drugs 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 229940087857 lupron Drugs 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 229940087732 matulane Drugs 0.000 description 1
• 229940087412 maxidex Drugs 0.000 description 1
• 210000002050 maxilla Anatomy 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
• QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
• 210000001370 mediastinum Anatomy 0.000 description 1
• 229940064748 medrol Drugs 0.000 description 1
• 229940090004 megace Drugs 0.000 description 1
• 229960001786 megestrol Drugs 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 210000000713 mesentery Anatomy 0.000 description 1
• 229960004635 mesna Drugs 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000004066 metabolic change Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 description 1
• 229960003058 methotrexate sodium Drugs 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 229940087004 mustargen Drugs 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 229940090009 myleran Drugs 0.000 description 1
• 210000000754 myometrium Anatomy 0.000 description 1
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
• LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
• 210000001989 nasopharynx Anatomy 0.000 description 1
• 229940086322 navelbine Drugs 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 229960000801 nelarabine Drugs 0.000 description 1
• 201000011682 nervous system cancer Diseases 0.000 description 1
• 229940082926 neumega Drugs 0.000 description 1
• 229940029345 neupogen Drugs 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 208000029974 neurofibrosarcoma Diseases 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 229940080607 nexavar Drugs 0.000 description 1
• 229940099637 nilandron Drugs 0.000 description 1
• 229950010203 nimotuzumab Drugs 0.000 description 1
• 229940109551 nipent Drugs 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 108091008104 nucleic acid aptamers Proteins 0.000 description 1
• 229960002700 octreotide Drugs 0.000 description 1
• 229960001494 octreotide acetate Drugs 0.000 description 1
• 210000002747 omentum Anatomy 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 229940100027 ontak Drugs 0.000 description 1
• 108010046821 oprelvekin Proteins 0.000 description 1
• 229940003515 orapred Drugs 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229960002502 paclitaxel protein-bound Drugs 0.000 description 1
• 238000007427 paired t-test Methods 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 229960000402 palivizumab Drugs 0.000 description 1
• 229940046231 pamidronate Drugs 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229940096763 panretin Drugs 0.000 description 1
• 210000003681 parotid gland Anatomy 0.000 description 1
• 229940097097 pediapred Drugs 0.000 description 1
• HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
• 108010001564 pegaspargase Proteins 0.000 description 1
• 229960001744 pegaspargase Drugs 0.000 description 1
• 108010044644 pegfilgrastim Proteins 0.000 description 1
• 229960001373 pegfilgrastim Drugs 0.000 description 1
• 229960005079 pemetrexed Drugs 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 229940063179 platinol Drugs 0.000 description 1
• 210000004224 pleura Anatomy 0.000 description 1
• 229960001237 podophyllotoxin Drugs 0.000 description 1
• YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
• YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• 229940096111 prelone Drugs 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 229940029359 procrit Drugs 0.000 description 1
• 229940087463 proleukin Drugs 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 229940121649 protein inhibitor Drugs 0.000 description 1
• 239000012268 protein inhibitor Substances 0.000 description 1
• 230000006916 protein interaction Effects 0.000 description 1
• 229940034080 provenge Drugs 0.000 description 1
• 229940117820 purinethol Drugs 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000008672 reprogramming Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 229940120975 revlimid Drugs 0.000 description 1
• 229940061969 rheumatrex Drugs 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 229940072272 sandostatin Drugs 0.000 description 1
• 108700014314 sandostatinLAR Proteins 0.000 description 1
• 108010038379 sargramostim Proteins 0.000 description 1
• 229960002530 sargramostim Drugs 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 230000009758 senescence Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 210000001599 sigmoid colon Anatomy 0.000 description 1
• 229960000714 sipuleucel-t Drugs 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 229940088542 solu-cortef Drugs 0.000 description 1
• 229940087854 solu-medrol Drugs 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 235000013599 spices Nutrition 0.000 description 1
• 230000037436 splice-site mutation Effects 0.000 description 1
• 238000001370 static light scattering Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 229940034785 sutent Drugs 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 229940095374 tabloid Drugs 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 229940120982 tarceva Drugs 0.000 description 1
• 229940099419 targretin Drugs 0.000 description 1
• RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 108091035539 telomere Proteins 0.000 description 1
• 102000055501 telomere Human genes 0.000 description 1
• 210000003411 telomere Anatomy 0.000 description 1
• 229940061353 temodar Drugs 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
• 150000003505 terpenes Chemical class 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229960003433 thalidomide Drugs 0.000 description 1
• 229940034915 thalomid Drugs 0.000 description 1
• 229940110675 theracys Drugs 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 208000008732 thymoma Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 230000003868 tissue accumulation Effects 0.000 description 1
• 230000009258 tissue cross reactivity Effects 0.000 description 1
• 210000002105 tongue Anatomy 0.000 description 1
• 229940035307 toposar Drugs 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• 229940100411 torisel Drugs 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 229940066958 treanda Drugs 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• 229940086984 trisenox Drugs 0.000 description 1
• 229940094060 tykerb Drugs 0.000 description 1
• 238000007473 univariate analysis Methods 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 229940099039 velcade Drugs 0.000 description 1
• 229940065658 vidaza Drugs 0.000 description 1
• 229960004982 vinblastine sulfate Drugs 0.000 description 1
• AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
• 229960002166 vinorelbine tartrate Drugs 0.000 description 1
• GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
• 229960000237 vorinostat Drugs 0.000 description 1
• 210000003905 vulva Anatomy 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 229940053867 xeloda Drugs 0.000 description 1
• 229940053890 zanosar Drugs 0.000 description 1
• 229940033942 zoladex Drugs 0.000 description 1
• 229960004276 zoledronic acid Drugs 0.000 description 1
• 229940061261 zolinza Drugs 0.000 description 1
• 229940002005 zometa Drugs 0.000 description 1